Methods
An email was sent to pharmacists and pharmacy technicians through the CF Foundation LISTSERV and all responses regarding ELX/TEZ/IVA use in children 6 to 11 years of age were collected. Data included patient demographics (age, genetic mutations, weight, previous CFTR modulator use and regimen), insurance type (state or commercial), prior authorization attempts and overall approval or denial, and ELX/TEZ/IVA regimen. Descriptive statistics were used to analyze data and a prior authorization approval rate was calculated.